Potency and Spectrum of Activity of AN3365, a Novel Boron-Containing Protein Synthesis Inhibitor,Tested against Clinical Isolates of Enterobacteriaceae and Nonfermentative Gram-Negative Bacilli |
| |
| Authors: | Rodrigo E Mendes M R K Alley Helio S Sader Douglas J Biedenbach Ronald N Jones |
| |
| Institution: | JMI Laboratories, North Liberty, Iowa, USAa;Anacor Pharmaceuticals, Palo Alto, California, USAb;Tufts University School of Medicine, Boston, Massachusetts, USAc |
| |
| Abstract: | AN3365 (MIC50/90, 0.5/1 μg/ml) was active against Enterobacteriaceae, including a subset of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains (MIC50/90, 1/2 μg/ml). AN3365 inhibited 98.0 and 92.2% of wild-type (MIC50/90, 2/8 μg/ml) and carbapenem-resistant (MIC50/90, 4/8 μg/ml) Pseudomonas aeruginosa strains, respectively, at ≤8 μg/ml. AN3365 also demonstrated activity against wild-type Acinetobacter baumannii (MIC50/90, 2/8 μg/ml) and Stenotrophomonas maltophilia (MIC50/90, 2/4 μg/ml), while it was less active against multidrug-resistant A. baumannii (MIC50/90, 8/16 μg/ml) and Burkholderia cepacia (MIC50/90, 8/32 μg/ml). |
| |
| Keywords: | |
|
|
